Table 1 (abstract P03). Baseline characteristics and interim analysis data of patients with TRAPS

Number of patients, N

16

13

10

6

Females (%)

11 (69)

9 (69)

7 (70)

3 (50)

Median duration of prior CAN therapy at baseline, years (min; max)

1.0 (0; 4)

1.0 (0; 4)

1.0 (0; 4)

1.5 (0; 2)

Number (%*) of patients in disease remission (physician assessment)

9 (60.0)

9 (81.8)

7 (77.8)

4 (80.0)

Physician Global Assessment, percentage of absent/mild-moderate/severe rating

40 / 53 / 0

82 / 9 / 0

44 / 44 / 11

80 / 20 / 0

Patient assessment of current disease activity; 0–10, median (min; max)

1.5 (0; 5)

1.0 (0; 4)

1.0 (0; 6)

0.0 (0; 3)

Patient assessment of current fatigue; 0–10, median (min; max)

2.0 (0; 8)

1.0 (0; 7)

2,5 (0; 8)

4.0 (0; 7)

Number (%*) of patients without impairment of social life by the disease

4 (50)

5 (63)

2 (33)

3 (60)

CRP, SAA median (mg/dl)

0.1/0.5

0.1/0.4

0.1/0.4)

0.0/0.3